tbuckley/cabot-search huggingface dataset:
Decreased Jagged1 expression in vascular smooth muscle cells delays endothelial regeneration in arteriovenous graft
Authors: Qunying Guo, Fengzhang Huang, Ying Qing, Shaozhen Feng, Xiaoguang Xiao, Yun Wang, Ming Liang, Tao Wang, William E Mitch, Jizhong Cheng
Journal: Cardiovascular Research (2020)

It is well-established that endothelial dysfunction promotes activation of vascular smooth muscle cell (VSMC). Whether decreased accumulation of VSMCs affects endothelial regeneration and functions in arteriovenous graft (AVG) remodelling has not been studied. We sought to identify mechanisms by which the Notch ligand, Jagged1, in VSMCs regulates endothelial cell (EC) functions in AVGs.AVGs were created in transgenic mice bearing VSMC-specific knockout (KO) or overexpression of Jagged1. VSMC migration, EC regeneration, and its barrier functions as well as AVG remodelling were evaluated. Jagged1 expression was induced in VSMCs of neointima in the AVGs. Jagged1 KO in VSMCs inhibited the accumulation of extracellular matrix as well as VSMC migration. Fewer α-SMA-positive VSMCs were found in AVGs created in VSMC-specific Jagged1 KO mice (VSMCJagged1 KO mice) vs. in WT mice. Decreased VSMCs in AVGs were associated with deterioration of EC functions. In AVGs created in transgenic mice bearing Jagged1 KO in VSMCs exhibited delayed EC regeneration and impaired EC barrier function. Barrier dysfunction of ECs increased inflammatory cell infiltration and dysregulation of AVG remodelling and arterialization. The increased expression of IL-1β in macrophages was associated with expression of adhesion markers in ECs in AVGs created in VSMCJagged1 KO mice. In contrast, AVGs created in mice with overexpression of Jagged1 in VSMCs exhibited improved EC regeneration plus decreased macrophage infiltration. This led to AVG remodelling and arterialization. In co-cultures of ECs and VSMCs, Jagged1 deficiency in VSMCs suppressed N-cadherin and integrin β3 expression in ECs. Inhibition of integrin β3 activation delayed EC spreading and migration. Notably, Jagged1 overexpression in VSMCs or treatment with recombinant Jagged1 stimulated the expression of N-cadherin and integrin β3 in ECs. Jagged1-induced responses were blocked by inhibition of Notch signalling.Jagged1 expression in VSMCs maintains EC barrier functions and blocks infiltration of macrophages. These responses promote remodelling and arterialization of AVGs.
Evaluation of PTEN and PIK3CA Status in Breast Cancer for Patient Selection
Authors: V. Serra, J. Rodon, C.M. Aura, A. Vivancos, K. Stemke-Hale, H. Hibshoosh, Y. Wang, S. Ramon Y. Cajal, J. Tabernero, J. Baselga
Journal: Annals of Oncology (2012)
Mutact: An Observational Study of EGFR Mutation Status and Management of Patients with Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Authors: P. Souquet, P. Fournel, C. Locher, J.C. Sabourin, E. Garcia, M. Licour, N. Karam
Journal: Annals of Oncology (2012)
Time to Brain Metastasis (TTBM) from Initial Diagnosis of Distant Metastasis in Breast Cancer: Prediction of TTBM According to Breast Cancer Subtypes and Treatment Effect
Authors: Y.H. Park, H.K. Ahn, S. Park, C.H. Maeng, S.J. Lee, J.S. Ahn, Y.-H. Im
Journal: Annals of Oncology (2012)
Simultaneous Detection of Multicytotoxic Drugs on Occupational Environment by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis
Authors: T. Ogawa, M. Yonemura, K. Kawasumi, Y. Aoyagi, S. Ueno, Y. Ichida, Y. Ohe, K. Endo, K. Izumi
Journal: Annals of Oncology (2012)
Expression and Clinical Importance of E-Cadherin, Dysadherin and Chemokine Ligand 2 (CCL2) in Renal Cell Carcinoma (RCC)
Authors: U. Demirci, M. Yaman, S. Buyukberber, O. Ekinci, S. Ozkan, U. Coskun, M. Benekli, A. Ozet, Ü.E. Bagriacik
Journal: Annals of Oncology (2012)
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Authors: Guotai Xu, Sagar Chhangawala, Emiliano Cocco, Pedram Razavi, Yanyan Cai, Jordan E Otto, Lorenzo Ferrando, Pier Selenica, Erik Ladewig, Carmen Chan, Arnaud Da Cruz Paula, Matthew Witkin, Yuanming Cheng, Jane Park, Cristian Serna-Tamayo, HuiYong Zhao, Fan Wu, Mirna Sallaku, Xuan Qu, Alison Zhao, Clayton K Collings, Andrew R. D’Avino, Komal Jhaveri, Richard Koche, Ross L. Levine, Jorge S. Reis-Filho, Cigall Kadoch, Maurizio Scaltriti, Christina S. Leslie, José Baselga, Eneda Toska
Journal: Nature Genetics (2020)
Investigation of Mg–Zn–Y–Nd alloy for potential application of biodegradable esophageal stent material
Authors: Shuo Wang, Xueqi Zhang, Jingan Li, Changsheng Liu, Shaokang Guan
Journal: Bioactive Materials (2020)

In recent years, due to unhealthy dietary habits and other reasons, advanced esophageal cancer patients are on the rise, threatening human health and life safety at all times. Stents implantation as an important complementary or alternative method for chemotherapy has been widely applied in clinics. However, the adhesion and proliferation of pathological cells, such as tumor cells, fibroblasts and epithelial cells, may interfere the efficacy of stents. Further multiple implantation due to restenosis may also bring pain to patients. In this contribution, we preferred a biodegradable material Mg-Zn-Y-Nd alloy for potential application of esophageal stent. The hardness testing showed that Mg-Zn-Y-Nd alloy owned less mechanical properties compared with the commercial esophageal stents material, 317L stainless steel (317L SS), while Mg-Zn-Y-Nd displayed significantly better biodegradation than 317L SS. Cell apoptosis assay indicated Mg-Zn-Y-Nd inhibited adhesion and proliferation of tumor cells, fibroblasts and epithelial cells. Our research suggested potential application of Mg-Zn-Y-Nd alloy as a novel material for biodegradable esophageal stent.
Clare Gerada: Doctors deserve to work in an environment that doesn’t make them sick
Authors: Clare Gerada
Journal: BMJ (2020)

I recently had a big birthday, one that allows me to have a free London bus pass. This milestone has caused me to reflect on my long career, particularly my work with the NHS.

I’ve mentioned before that I started working in the NHS at 14. Initially I worked on Saturdays in a local pharmacy before becoming the Saturday morning receptionist at my father’s singlehanded general practice. To spare you the maths, I’ve now been involved with the NHS for 46 years—a long time by anyone’s standards. I want to …
Exercise‐induced allergic reactions on desensitization to wheat after rush oral immunotherapy
Authors: Tomoko Furuta, Kajiyo Tanaka, Kazunori Tagami, Teruaki Matsui, Shiro Sugiura, Naoyuki Kando, Yuuki Kanie, Michihiro Naito, Hidehiko Izumi, Akira Tanaka, Sigrid Sjölander, Tomoharu Yokooji, Hiroaki Matsuo, Komei Ito
Journal: Allergy (2020)

The effect of oral immunotherapy (OIT) on wheat allergy is promising in terms of the potential to obtain desensitization; however, the frequency of exercise-induced allergic reactions on desensitization (EIARDs) and the associated risk factors remain to be determined.Twenty-five patients underwent rush OIT for wheat allergy, and 21 achieved the full-dose intake of wheat products (5 g of wheat protein). Exercise-provocation tests were repeatedly performed after the ingestion of a full-dose wheat product. The time-course of the levels of the specific IgEs (sIgE) to wheat extract, total gliadin, deamidated gliadin, recombinant gliadin components (α/β-, γ- and ω-5-), and glutenin (high and low molecular weight) components was analyzed using ImmunoCAP® , ELISA, or IgE immunoblotting.Fourteen patients (66.7%) were diagnosed as EIARD+, which remained 5 years after rush OIT in 11 patients (52.4%). There were no differences in the clinical backgrounds of the EIARD+ and EIARD- patients. However, EIARD+ patients showed significantly higher sIgE levels to all gliadin and glutenin components than EIARD- patients before OIT. The sIgE levels to each component decreased equally after 1 and 2 years of OIT. On IgE immunoblotting, sera from all patients reacted to the multiple gluten bands, and some reacted to the water-soluble bands. The intensity of all IgE-reactive bands also became equally lighter after OIT.EIARDs were frequently observed and remained for a long period after successful OIT for wheat allergy. None of the specific wheat components were found to contribute to EIARDs.
Concomitant Chemoradiation gives Significant Survival and Hrqol Benefits in Patients with Locally Advanced Stage III Non Small Cell Lung Cancer (NSCLC) Not Eligible for Radical Treatment: A Randomized Trial by the Norwegian Lung Cancer Study Group
Authors: H.H. Strøm, S. Sundstrøm, N. Helbekkmo, R. Bremnes, U. Aasebø
Journal: Annals of Oncology (2012)
Arades Trial: A First-in-Man, Open-Label, Phase I/II Safety, Pharmacokinetic, and Proof-of-Concept Study of ODM-201 in Patients (PTS) with Progressive Metastatic Castration-Resistant Prostate Cancer (MCRPC)
Authors: C. Massard, N. James, S. Culine, R. Jones, A. Vuorela, M. Mustonen, K. Fizazi
Journal: Annals of Oncology (2012)
Computed Tomography (CT) Changes Precede Malignant Spinal Cord Compression (SCC) in Patients with Advanced Prostate Cancer (APC)
Authors: A.G. Omlin, C. Pezaro, D. Mukherji, D. Bianchini, G. Attard, A. Mulick Cassidy, C. Parker, D. Dearnaley, J.S. de Bono, N. Tunariu
Journal: Annals of Oncology (2012)
Dicer and Drosha Expression and Response to Bevacizumab-Based Therapy in Advanced Colorectal Cancer Patients
Authors: A. Zoccoli, M. Iuliani, F. Pantano, G. Schiavon, R. Ratta, P. Correale, A. Onetti Muda, D. Santini, G. Tonini, B. Vincenzi
Journal: Annals of Oncology (2012)
A review of cancer immunotherapy toxicity
Authors: Lucy Boyce Kennedy, April K. S. Salama
Journal: CA A Cancer Journal for Clinicians (2020)

Abstract Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. These toxicities often require specific management, which can include steroids and immune‐modulating therapy and for which consensus guidelines have been published. This review will focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.
Key determinants of patient experience in oncology: Results from a national online survey.
Authors: Christopher G. Lis, Steve Wood, Mark Rodeghier, Harold Taylor, James F. Grutsch, Digant Gupta
Journal: Journal of Clinical Oncology (2013)

e17502 Background: Evaluation of patient experience provides important data on the patient’s perception of the quality of care and treatment delivered by physicians, paramedical staff and the hospital as a whole. There are limited data on the most significant determinants of patient experience in the oncology setting. In a national sample of cancer patients, we investigated the key self-reported factors influencing overall patient experience. Methods: A national random sample of 724 patients undergoing treatment for cancer in a hospital setting between Jan 2009 and Dec 2011. Using a combination of professional and scholarly literature and focus groups, the survey instrument was developed employing an identified set of 13 patient experience factors, an overall patient experience measure and relevant demographic variables. Patients were invited via messages appearing randomly on oncology-oriented physician profile pages, content pages and hospital profile pages from the Healthgrades web properties. Patients were asked to rate their cancer treatment experience on a 5-point scale from “very poor” to “very good” on the 13 patient experience factors. Participants were also asked to identify factors that contributed the most to their overall patient experience. Results: 181 were males and 543 were females. Age distribution was 5-24 (n=8), 25-44 (n=95), 45-54 (n=197), 55-64 (n=259) and 65+ (n=159). Top 5 tumor types were breast (n=284), gynecological (n=78), colorectal (n=47), lung (n=34) and prostate (n=28). Tumor stage at the time of receiving care was I, 210; II, 149; III, 133; IV, 128; and unknown, 104.481 (66.4%) patients were “very satisfied” with their overall experience. The three most important determinants of patient experience as reported by patients were "a compassionate team of care providers" (49.2%), "a knowledgeable, competent physician” (48.9%) and "treatment as a human being and not just a person with a disease" (28.3%). Conclusions: We identified three key determinants of overall patient experience in oncology. Oncology care providers can use data on patient experience to design and track quality improvement over time as well as recognize and expeditiously resolve unmet needs of patients in real-time.
P-0270 Impact of Kras and Braf Gene Mutation Status on Outcomes of Chemotherapy in Combination with Bevacizumab in Metastatic Colorectal Cancer
Authors: Luigi Rossi, Enzo Veltri, Angelo Zullo, Federica Zoratto, Maria Colonna, Flavia Longo, Marcella Mottolese, Diana Giannarelli, Luigi Ruco, Adriana Romiti, Viola Barucca, Daniela Adua, Giovanni Baiano, Giuseppe Giannini, Stefano Nardi, Vittoria Lapadula, Silverio Tomao
Journal: Annals of Oncology (2012)
A Bis-Indole–Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity
Authors: Keshav Karki, Gus A. Wright, Kumaravel Mohankumar, Un-Ho Jin, Xing-Han Zhang, Stephen Safe
Journal: Cancer Research (2020)

Abstract PD-L1 is expressed in tumor cells and its interaction with PD-1 plays an important role in evading immune surveillance; this can be overcome using PD-L1 or PD-1 immunotherapy antibodies. This study reports a novel approach for targeting PD-L1. In human breast cancer cell lines and 4T1 mouse mammary tumor cells, PD-L1 expression was regulated by the nuclear receptor NR4A1/Sp1 complex bound to the proximal germinal center (GC)-rich region of the PD-L1 gene promoter. Treatment of breast cancer cells with bis-indole–derived NR4A1 antagonists including 1,1-bis(3′-indolyl)-1-(3-chloro-4-hydroxy-5-methoxyphenyl)methane (Cl-OCH3) decreased expression of PD-L1 mRNA, promoter-dependent luciferase activity, and protein. In in vivo studies using a syngeneic mouse model bearing orthotopically injected 4T1 cells, Cl-OCH3 decreased tumor growth and weight and inhibited lung metastasis. Cl-OCH3 also decreased expression of CD3+/CD4+/CD25+/FoxP3+ regulatory T cells and increased the Teff/Treg ratio. Therefore, the potent anticancer activities of NR4A1 antagonists are also accompanied by enhanced antitumor immunity in PD-L1–expressing triple-negative breast cancer and thus represent a novel class of drugs that mimic immunotherapy. Significance: These findings show that the orphan nuclear receptor NR4A1 controls PD-L1 expression and identify a chemical probe capable of disrupting this regulatory axis.
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure
Authors: Alana A. Lewis, Colby R. Ayers, Elizabeth Selvin, Ian Neeland, Christie M. Ballantyne, Vijay Nambi, Ambarish Pandey, Tiffany M. Powell-Wiley, Mark H. Drazner, Mercedes R. Carnethon, Jarett D. Berry, Stephen L. Seliger, Christopher R. DeFilippi, James A. de Lemos
Journal: Circulation (2020)

Background: A malignant subphenotype of left ventricular hypertrophy (LVH) has been described, in which minimal elevations in cardiac biomarkers identify individuals with LVH at high risk for developing heart failure (HF). We tested the hypothesis that a higher prevalence of malignant LVH among blacks may contribute to racial disparities in HF risk. Methods: Participants (n=15 710) without prevalent cardiovascular disease were pooled from 3 population-based cohort studies, the ARIC Study (Atherosclerosis Risk in Communities), the DHS (Dallas Heart Study), and the MESA (Multi-Ethnic Study of Atherosclerosis). Participants were classified into 3 groups: those without ECG-LVH, those with ECG-LVH and normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) &lt;6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) &lt;100 pg/mL), and those with ECG-LVH and abnormal levels of either biomarker (malignant LVH). The outcome was incident HF. Results: Over the 10-year follow-up period, HF occurred in 512 (3.3%) participants, with 5.2% in black men, 3.8% in white men, 3.2% in black women, and 2.2% in white women. The prevalence of malignant LVH was 3-fold higher among black men and women versus white men and women. Compared with participants without LVH, the adjusted hazard ratio for HF was 2.8 (95% CI, 2.1–3.5) in those with malignant LVH and 0.9 (95% CI, 0.6–1.5) in those with LVH and normal biomarkers, with similar findings in each race/sex subgroup. Mediation analyses indicated that 33% of excess hazard for HF among black men and 11% of the excess hazard among black women was explained by the higher prevalence of malignant LVH in blacks. Of black men who developed HF, 30.8% had malignant LVH at baseline, with a corresponding population attributable fraction of 0.21. The proportion of HF cases occurring among those with malignant LVH, and the corresponding population attributable fraction, were intermediate and similar among black women and white men and lowest among white women. Conclusions: A higher prevalence of malignant LVH may in part explain the higher risk of HF among blacks versus whites. Strategies to prevent development or attenuate risk associated with malignant LVH should be investigated as a strategy to lower HF risk and mitigate racial disparities.
Response to Neoadjuvant Therapy and Disease Free Survival and Overall Survival in Patients with Triple-Negative Breast Cancer (TNBC): Single Center Experience
Authors: T. Pascual, E. Ciruelos, L. Manso, I. Ghanem, R.A. Manneh, C. Mendiola, D. Lora, H. Cortes-Funes
Journal: Annals of Oncology (2012)
The Role of Cox-2 and KI-67 Overexpression in the Prediction of Pathologic Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy
Authors: A. Taghizadeh Kermani, A. Jafarian, J. Esmaeili, N. Mohammadian Roshan, M. Seilanian Toosi, A. Omidi Ashrafi, M. Karimi Shahri
Journal: Annals of Oncology (2012)
Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma
Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Journal: Journal of Hematology & Oncology (2020)

Abstract Background Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms involved in RCC is of great significance for improving the survival of patients with advanced RCC. Acylglycerol kinase (AGK) is a newly discovered lipid kinase that has been reported to be a potent oncogene that may be involved in the regulation of malignant progression in a variety of tumours. However, the expression and biological characteristics of the AGK gene in RCC remain unclear. Methods AGK expression was quantified by quantitative real-time PCR, Western blotting and immunohistochemistry in RCC cell lines and paired patient tissues. Kaplan-Meier method and Cox proportional hazards models were used to evaluate the prognostic value of AGK in human RCC tissue samples. Chi-squared test was performed to analyse the correlation between AGK expression and the clinicopathological features. Stable overexpression and knockdown of AGK in RCC cells was constructed with lentivirus. The oncogenic effects of AGK in human RCC progression were investigated using assays of colony formation, anchorage-independent growth, EdU assay, cell cycle analysis, wound-healing, trans-well analysis and xenograft tumour model. GSEA and KEGG analysis were conducted to detect the potential pathway of AGK involved in RCC. These results were further confirmed using the luciferase reporter assays, immunofluorescence and in vivo experiments. Results AGK expression is significantly elevated in RCC and closely related to the malignant development and poor prognosis in RCC patients. By in vitro and in vivo experiments, AGK was shown to enhance the proliferation of RCC cells by promoting the transition from the G1 phase to the S phase in the cell cycle and to enhance the migration and invasion by promoting epithelial-mesenchymal transition. By activating the PI3K/AKT/GSK3β signalling pathway in RCC, AGK can increase nuclear accumulation of β-catenin, which further upregulated TCF/LEF transcription factor activity. Conclusions AGK promotes the progression of RCC via activating the PI3K/AKT/GSK3β signalling pathway and might be a potential target for the further research of RCC.
Treatment Results of Definitive Chemoradiotherapy with Elective Nodal Irradiation for Patients with Clinical Stage I (T1B) Esophageal Squamous Cell Carcinoma
Authors: H. Miyamoto, T. Kojima, T. Yano, S. Zenda, N. Fuse, T. Yoshino, T. Doi, K. Kaneko, T. Akimoto, A. Ohtsu
Journal: Annals of Oncology (2012)
Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy
Authors: Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, Pierre I. Karakiewicz
Journal: Journal of the National Comprehensive Cancer Network (2020)

Background: Conditional survival (CS) may reveal important differences in cancer-specific mortality (CSM) among patients with nonmetastatic renal cell carcinoma (nmRCC). This study assessed CS according to T and N stages in patients treated surgically for nmRCC. Patients and Methods: Within the SEER database (2001–2015), all patients with nmRCC treated with either partial or radical nephrectomy were identified. CSM-free estimates according to T and N stage and substage groupings (pT1aN0–pT4N0 and pTanyN1) and multivariable Cox regression models with adjustment for Fuhrman grade and histologic subtype were assessed. Results: According to T and N stage and substage groupings, the following patients were included in the study: 35,966 (46.2%) with pT1aN0 disease; 18,858 (24.2%) with pT1bN0; 5,977 (7.7%) with pT2aN0; 2,511 (3.2%) with pT2bN0; 11,839 (15.2%) with pT3aN0; 1,037 (1.3%) with pT3b–cN0; 402 (0.5%) with pT4N0; and 1,302 (1.7%) with pTanyN1. Conditional CSM-free survival estimates were 98.2% at 1 year versus 98.0% at 10 years of event-free follow-up for patients with pT1aN0 disease, relative to baseline. Conversely, pT4N0/pTanyN1 conditional CSM-free survival estimates were 55.8% at 1 year versus 77.9% at 8 years of event-free follow-up. Attrition due to mortality was highest in patients with pT4N0/pTanyN1 disease. In multivariable Cox regression analyses, T stage, tumor grade, and histologic subtype represented independent predictors, but no interactions were identified. Conclusions: Tumor stage and its substages represent extremely important determinants of prognosis after lengthy event-free follow-up. The recorded observations have critical importance for physicians regarding patient follow-up and counseling.
A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Authors: Hua Zhang, Lei Gao, Li Liu, Jishi Wang, Sanbin Wang, Li Gao, Cheng Zhang, Yao Liu, Peiyan Kong, Jia Liu, Jiaping He, Yu Han, Hua Shi, Yan He, Xun Ye, Yi Zhao, Wei Cao, Lianjun Shen, Xi Zhang
Journal: Blood (2019)
Dopamine-Evoked Synaptic Regulation in the Nucleus Accumbens Requires Astrocyte Activity
Authors: Michelle Corkrum, Ana Covelo, Justin Lines, Luigi Bellocchio, Marc Pisansky, Kelvin Loke, Ruth Quintana, Patrick E. Rothwell, Rafael Lujan, Giovanni Marsicano, Eduardo D. Martin, Mark J. Thomas, Paulo Kofuji, Alfonso Araque
Journal: Neuron (2020)